What is the clinical evidence from this study?

Study design: Letter. Population: Diabetes Mellitus. Intervention: Aspirin. Primary outcome: primary endpoint (9% reduction, p=nonsignificant).

What question did this study set out to answer?

The aim is to evaluate the efficacy of low-dose aspirin for primary prevention of cardiovascular diseases in individuals with diabetes.

May 25, 2007Diabetes CareOpen Access

Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A Scientific Statement From the American Heart Association and the American Diabetes Association

View Full Paper

Ask AI

Bookmark

Why the study?

Does low-dose aspirin prevent cardiovascular diseases in individuals with diabetes aged >40 years or with additional risk factors?

Population

Individuals with diabetes aged >40 years or who have additional risk factors

Design

Editorial

Authors

ANAntonio NicolucciCenter for Outcomes Research and Clinical Epidemiology GBGiorgia De BerardisCenter for Outcomes Research and Clinical Epidemiology MSMichele SaccoUniversity of Verona

Discussion

Member takes

Implication

This commentary critiques the ADA/AHA recommendation for low-dose aspirin in primary prevention for diabetic patients, highlighting the limited supporting evidence.

Key Points

The aim is to evaluate the efficacy of low-dose aspirin for primary prevention of cardiovascular diseases in individuals with diabetes.
Recommendation based on data from the Early Treatment Diabetic Retinopathy Study.
Focus on individuals with diabetes aged over 40 or with additional cardiovascular risk factors.
Assessment of treatment with 650 mg aspirin over 5 years.
Aspirin treatment was associated with a nonsignificant 9% reduction in primary endpoint.
Evidence primarily derived from the Early Treatment Diabetic Retinopathy Study.
Recommendation applies to all individuals with diabetes meeting the age and risk factor criteria.

Structured PICO

Does low-dose aspirin prevent cardiovascular diseases in individuals with diabetes aged >40 years or with additional risk factors?

Population

Individuals with diabetes aged >40 years or who have additional risk factors

Intervention

Low doses of aspirin

Outcome

Primary prevention of cardiovascular diseaseshard clinical

Main Result

Effect estimate: 9% reduction

p-value: p=nonsignificant

This commentary critiques the ADA/AHA recommendation for low-dose aspirin in primary prevention for diabetic patients, highlighting the limited supporting evidence.

Cite This Study

Nicolucci et al. (2007) conducted a letter in Diabetes Mellitus. Aspirin was evaluated on primary endpoint (9% reduction, p=nonsignificant). In the Early Treatment Diabetic Retinopathy Study, treatment with 650 mg aspirin for 5 years was associated with a nonsignificant 9% reduction in the primary endpoint among diabetic patients.

synapsesocial.com/papers/6a696ea4a7344df3fa47ef67 https://doi.org/10.2337/dc07-0220

Topics

Cardiovascular prevention

View Full Paper

Ask AI

Bookmark

Implication

This commentary critiques the ADA/AHA recommendation for low-dose aspirin in primary prevention for diabetic patients, highlighting the limited supporting evidence.

Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A Scientific Statement From the American Heart Association and the American Diabetes Association

Discussion

Member takes

Implication

Key Points

Structured PICO

Main Result

Cite This Study

Topics

Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A Scientific Statement From the American Heart Association and the American Diabetes Association

Discussion

Member takes

Implication

Key Points

Structured PICO

Main Result

Cite This Study

Also Consider

Topics

Also Consider